drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous CAR-T cell therapy in which patient T cells are engineered to express a chimeric antigen receptor using the BAFF (BLyS) ligand as the binding domain, enabling multi-antigen recognition of BAFF-R, BCMA, and TACI to target malignant plasma cells in relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a BAFF (BLyS) ligand–based chimeric antigen receptor that binds BAFF-R, BCMA, and TACI on malignant plasma/B-lineage cells. Antigen engagement activates CAR signaling to drive T‑cell proliferation and targeted cytotoxicity (perforin/granzyme and cytokine-mediated killing), providing multi-antigen recognition to reduce antigen escape in relapsed/refractory multiple myeloma.
drug_name
LMY-920 (BAFF-ligand CAR-T cells)
nct_id_drug_ref
NCT05546723